Skip to search formSkip to main contentSkip to account menu

RPMI-8226

A lymphoblast-like cell line established from the peripheral blood of a 61 year old male patient with multiple myeloma (IgG lambda-type).
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2013
2013
Triazole-based inhibitors of geranylgeranyltransferase II.
Highly Cited
2011
Highly Cited
2011
Cyclin-dependent kinase inhibitor, P276-00 induces apoptosis in multiple myeloma cells by inhibition of Cdk9-T1 and RNA polymerase II-dependent transcription.
2010
2010
Differential activities of thalidomide and isoprenoid biosynthetic pathway inhibitors in multiple myeloma cells.
Highly Cited
2009
Highly Cited
2009
Regioselective synthesis and stereochemical structure of anti-tumor active dispiro[3H-indole-3,2'-pyrrolidine-3',3''-piperidine]-2(1H),4''-diones.
  • A. S. Girgis
  • European journal of medicinal chemistry
  • 2009
  • Corpus ID: 1860783
Highly Cited
2007
Highly Cited
2007
Characterization of in vitro growth of multiple myeloma cells.
Highly Cited
2007
Highly Cited
2007
In vitro cytotoxic activity of Brazilian plant extracts against human lung, colon and CNS solid cancers and leukemia.
2007
2007
Synthesis of novel 3-amino-2-(4-chloro-2-mercaptobenzenesulfonyl)-guanidine derivatives as potential antitumor agents.
Highly Cited
2003
Highly Cited
2003
The Bisphosphonate Zoledronic Acid Induces Cytotoxicity in Human Myeloma Cell Lines with Enhancing Effects of Dexamethasone and Thalidomide
Bisphosphonates have recently been introduced in the therapeutic armamentarium for long-term treatment of patients with multiple… 
Highly Cited
2002
Highly Cited
2002
Growth inhibition and apoptosis of myeloma cells by the CDK inhibitor flavopiridol.
1999
1999
Isolation of human lymphocyte antigens class I-restricted cytotoxic T lymphocytes against autologous myeloma cells.
Peripheral blood T cells from a patient with multiple myeloma in complete remission were selected in vitro against an autologous… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)